Veracyte, Inc. (NASDAQ:VCYT) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:50 PM EDT
Company Participants
Marc Stapley – CEO & Director
Rebecca Chambers – Executive VP & CFO
Conference Call Participants
Kallum Titchmarsh – Morgan Stanley, Research Division
Presentation
Kallum Titchmarsh
Equity Analyst
Okay. I think we can get started. Kallum Titchmarsh here from the life sciences team at Morgan Stanley. Really pleased today to be joined by the team from Veracyte. We have Marc Stapley, CEO; and Rebecca Chambers, CFO. Before we get started, the good stuff, the disclosures. So please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures.
Question-and-Answer Session
Kallum Titchmarsh
Morgan Stanley, Research Division
So thank you, everyone, for joining. Marc, maybe just to set the stage for us, can you walk us through how 2025 has played out so far versus your initial expectations? Beyond the numbers, what are you most proud of? And what challenges would you maybe call out?
Marc Stapley
CEO & Director
Yes, I’m happy to, and thanks very much for having us here today. It’s our pleasure to be here. Maybe I can just cover some of the formalities as well and just remind everybody that to the extent we’d be making forward-looking statements, they’re expected to be covered under the safe harbor that can be found on our website at www.veracyte.com.
With that said, I appreciate the question around 2025. It’s been an interesting year for Veracyte so far with a lot of accomplishments under our belt. We actually feel very good about where we are, especially relative to where we were coming into the year. A couple of things, if I think about starting on the top line, the growth across the businesses has been — the core business has been really encouraging and impressive with Decipher growing 32% year-to-date and Afirma growing 9% year-to-date
Read the full article here